Bolt Biotherapeutics (BOLT) Stock Price, News & Analysis

Company Overview

Bolt Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company’s platform is designed to stimulate the body’s innate and adaptive immune systems to recognize and attack tumor cells.

Bolt’s technology includes Boltbody™ immune-stimulating antibody conjugates, or ISACs. These therapies are intended to combine the targeting capabilities of antibodies with immune-activating components that can recruit and enhance the activity of immune cells within the tumor microenvironment.

The company’s development programs have included BDC-1001, an investigational HER2-targeted ISAC for the treatment of HER2-expressing solid tumors, and BDC-3042, an investigational antibody intended to activate macrophages through the Dectin-2 pathway. Bolt is headquartered in Redwood City, California, and has conducted clinical development activities through studies involving patients in the United States and other countries. The company does not currently market an approved commercial product.

Key Stats

• Today's Range: $3.45 to $3.50
• 50-Day Range: $3.20 to $4.07
• 52-Week Range: $3.10 to $7.20
• Volume: 874 shs
• Average Volume: 26,608 shs
• Market Capitalization: $6.66 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $14.50
• Consensus Rating: Hold

Bolt Biotherapeutics Stock Analysis - MarketRank™

Bolt Biotherapeutics scored higher than 40% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Hold

Consensus Rating

Bolt Biotherapeutics has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Bolt Biotherapeutics has a consensus price target of $14.50, representing about 320.3% upside from its current price of $3.45.

Amount of Analyst Coverage

Bolt Biotherapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Bolt Biotherapeutics is -0.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Bolt Biotherapeutics is -0.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Bolt Biotherapeutics has a P/B Ratio of 0.25. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.06% of the float of Bolt Biotherapeutics has been sold short.

Short Interest Ratio / Days to Cover

Bolt Biotherapeutics has a short interest ratio ("days to cover") of 0.61, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Bolt Biotherapeutics has recently increased by 18.66%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Bolt Biotherapeutics does not currently pay a dividend.

Dividend Growth

Bolt Biotherapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Bolt Biotherapeutics this week, compared to 2 articles on an average week.

Search Interest

Only 2 people have searched for BOLT on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Bolt Biotherapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $128,361.00 in company stock.

Percentage Held by Insiders

9.40% of the stock of Bolt Biotherapeutics is held by insiders.

Percentage Held by Institutions

86.70% of the stock of Bolt Biotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/11/2026
• Today: 10/02/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:BOLT
• CIK: 1641281
• Web: www.boltbio.com
• Phone: 650-665-9295
• Fax: N/A
• Employees: 23
• Year Founded: 2015

Price Target and Rating

• Average Price Target for Bolt Biotherapeutics: $14.50
• High Price Target: $22.00
• Low Price Target: $7.00
• Potential Upside/Downside: +320.3%
• Consensus Rating: Hold
• Rating Score (0-4): 2.25
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($16.44)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$33.38 million
• Net Margins: -611.47%
• Pretax Margin: -611.47%
• Return on Equity: -126.23%
• Return on Assets: -54.70%

Debt

• Debt-to-Equity Ratio: 1.47
• Current Ratio: 2.61
• Quick Ratio: 2.61

Sales & Book Value

• Annual Sales: $7.70 million
• Price / Sales: 0.86
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $13.81 per share
• Price / Book: 0.25

Miscellaneous

• Outstanding Shares: 1,930,000
• Free Float: 1,745,000
• Market Cap: $6.66 million
• Optionable: Not Optionable
• Beta: 1.00